FTC approves final order in Baxter-Claris $625 million acquisition

By Mark Iandolo | Sep 8, 2017

WASHINGTON (Legal Newsline) — The Federal Trade Commission (FTC) announced Aug. 30 that, following a public comment period, it has approved a final order against Baxter International Inc., resolving allegations that Baxter’s proposed $625 million acquisition of Claris Lifesciences’ injectable drugs business would be anti-competitive.

According to the FTC, the acquisition without remedy would reduce current competition within the U.S. market for the anti-fungal agent fluconazole in saline intravenous bags. 

Additionally, the acquisition could have harmed future competition for intravenous milrinone, the FTC argued. Milrinone is used to dilate blood vessels, lower blood pressure and help blood flow better through a patient’s system.

To settle the allegations, Baxter agreed to divest all of Claris’s rights to fluconazole to Renaissance Lakewood LLC, a pharmaceutical company headquartered in New Jersey.

The FTC voted 2-0 to approve the final order. Kari Wallace of the Bureau of Competition is the staff contact for the case.

Want to get notified whenever we write about any of these organizations ?

Sign-up Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Baxter U.S. Federal Trade Commission

More News

The Record Network